ClinicalTrials.gg
CompletedNCT06870422Updated Apr 22, 2025

To Assess the Effect of the Special Condition on the Pharmacokinetics and Tolerability of the Esflurbiprofen Topical System (EFTS) in Healthy Volunteers.

A Phase 1 interventional study of Esflurbiprofen Topical System in Healthy, sponsored by Teikoku Seiyaku Co., Ltd.. Completed at 1 site in Germany. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-22.

Sponsored by Teikoku Seiyaku Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2025, 1 year 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

This study is a single-center, open-label, single-dose trial performed in a randomized, four-way, change-over design in healthy volunteers. The primary purpose of this study is to evaluate the effect of moderate heat, occlusion, and moderate exercise on pharmacokinetics. The secondary purpose is to characterize the effect of special conditions on the bioavailability and to evaluate patch adhesion and safety of TK-254RX and a residual amount of the patch.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Teikoku Seiyaku Co., Ltd. is the lead sponsor of 8 studies on the registry; none are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age: 18 to 64 years (inclusive)
  • body-mass index (): ≧18.5 kg/m² and ≦ 30.0 kg/m²
  • good state of health
  • non-smoker or ex-smoker for at least 6 months
  • written , after having been informed about benefits and potential risks of the clinical trial, as well as details of the insurance taken out to cover the subjects participating in the clinical trial

Exclusion criteria

Exclusion Criteria:

  • existing cardiac and/or haematological diseases or pathological findings, which might interfere with the safety or tolerability of the active ingredient
  • existing or history of hypertension and/or heart failure
  • existing hepatic and/or renal diseases or pathological findings, which might interfere with the safety or tolerability, and/or pharmacokinetics of the active ingredient
  • existing gastrointestinal diseases or pathological findings, which might interfere with the safety and tolerability of the active ingredient
  • history of gastrointestinal bleeding or perforation related to previous NSAID therapy
  • active, or history of ulcerative colitis, Crohn's disease, peptic ulceration or gastrointestinal haemorrhage
  • existing metabolic, endocrine and/or immunologic diseases or pathological findings, which might interfere with the safety or tolerability, and/or pharmacokinetics of the active ingredient
  • diabetes mellitus
  • hyperlipidaemia (LDL > 4.16 mmol/l, HDL \< 0.91 mmol/l, triglycerides > 2.28 mmol/l, cholesterol > 6.24 mmol/l)
  • history of relevant CNS and/or psychiatric disorders and/or currently treated CNS and/or psychiatric disorders
  • presence or history of acute or chronic diseases of the skin (e.g., atopic dermatitis (eczema), neurodermatitis, contact allergy, psoriasis, vitiligo, melanoma, squamous cell carcinoma), any dermatological condition or skin sensitivity which might interfere with the safety, tolerability, absorption and/or pharmacokinetics of the active ingredient
  • existing or history of bronchial asthma
  • known allergic reactions (e.g., bronchospasm, rhinitis, angioedema, or urticaria) to the active ingredients used, to acetylsalicylic acid or other NSAIDs, or to constituents of the pharmaceutical preparations
  • history of severe allergies or multiple drug allergies unless it is judged as not relevant for the clinical trial by the investigator
  • systolic blood pressure \< 90 or > 139 mmHg
  • diastolic blood pressure \< 60 or > 89 mmHg
  • heart rate \< 50 bpm or > 90 bpm
  • > 450 ms for men and > 470 ms for women
  • laboratory values out of normal range unless the deviation from normal is judged as not relevant for the clinical trial by the investigator
  • ASAT > 20% , ALAT > 10% ULN, > 20% ULN (except in case of existing Morbus Gilbert-Meulengracht deduced from anamnesis/medical history) and creatinine > 0.1 mg/dL ULN (limit of > 0.1 mg/dL correspondents to of > 9 µmol/l ULN).
  • positive anti--test (if positive to be verified by western blot), HBs-AG-test or anti--test
  • vaccination against COVID-19 within the last 4 weeks prior to individual intended IMP application
  • skin abnormality (e.g., tattoo (including tattoo that was removed), scar, sunburn, or obvious difference in skin colour), open sores, or excessive hair at the application site
  • acute or chronic diseases which may interfere with the pharmacokinetics of the IMP
  • history of or current drug or alcohol dependence
  • positive alcohol or drug test at screening examination
  • regular intake of alcoholic food or beverages of ≥ 24 g pure ethanol for male or ≥ 12 g pure ethanol for female per day
  • subjects who are on a diet which could affect the pharmacokinetics of the active ingredient
  • regular intake of caffeine containing food or beverages of ≥ 500 mg caffeine per day
  • blood donation or other blood loss of more than 400 ml within the last 2 months prior to individual enrolment of the subject
  • participation in a clinical trial with administration of any medicinal product during the last 2 months prior to individual enrolment of the subject
  • simultaneous participation in another clinical trial with active ingredients
  • regular treatment with any systemically available medication (except sexual and thyroid hormones)
  • subjects, who report a frequent occurrence of migraine attacks
  • positive pregnancy test at screening examination
  • pregnant or lactating women
  • female subjects who do not agree to apply highly effective methods
  • subject is vulnerable such as detained or committed to an institution by a court of law or by legal authorities or close affiliation with the sponsor or the investigational site (e.g., a close relative of the investigator, dependent person (e.g., employee of or student at the investigational site), employee of the sponsor or affiliates)
  • subjects suspected or known not to follow instructions
  • subjects who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to during their participation in the clinical trial
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    TK-254RX

    TK-254RX will be applied with no special condition

    Drug: Esflurbiprofen Topical System

  • Experimental
    TK-254RX with heat

    TK-254RX will be applied with moderate heat

    Drug: Esflurbiprofen Topical System

  • Experimental
    TK-254RX with occlusion

    TK-254RX will be applied with occlusion

    Drug: Esflurbiprofen Topical System

  • Experimental
    TK-254RX with exercise

    TK-254RX will be applied with 3 moderate exercise sessions

    Drug: Esflurbiprofen Topical System

Interventions

  • DrugEsflurbiprofen Topical System

    TK-254RX will be applied for one day

06

What researchers measure

Primary outcomes

  1. Assessing the effect of each intervention by Area under the plasma concentration versus time curve over 24 hours (AUC0-24) of S-flurbiprofen

    assessment of the effect of heat, occlusion, and moderate exercise on Test by use of AUC0-24 of S flurbiprofen

    Time frame: Day 1 to Day 2 for each period

  2. Assessing the effect of each intervention by peak plasma concentration (Cmax) of S-flurbiprofen

    assessment of the effect of heat, occlusion, and moderate exercise on Test determined by use of Cmax of S flurbiprofen

    Time frame: Day 1 to Day 2 for each period

  3. Assessing the effect of each intervention by area under the plasma concentration versus time curve from patch application to last measurement time point with a concentration value above lower limit of quantitation (AUC0-tlast) of S-flurbiprofen

    assessment of the effect of heat, occlusion, and moderate exercise on Test determined by use of AUC0-tlast of S flurbiprofen

    Time frame: Day 1 to Day 4 for each period

  4. Assessing the effect of each intervention by area under the plasma concentration versus time curve from patch application to infinity (AUC0-inf) of S-flurbiprofen

    assessment of the effect of heat, occlusion, and moderate exercise on Test determined by use of AUC0-inf of S flurbiprofen

    Time frame: Day 1 to Day 4 for each period

Secondary outcomes

  1. Assessing the effect of each intervention by area under the curve over 24 hours (AUC0-24)

    Characterisation of the effect of heat, occlusion, and moderate exercise on the bioavailability of Test determined by AUC0-24 of R-flurbiprofen and metabolites, if applicable

    Time frame: Day 1 to Day 2 for each period

  2. Assessing the effect of each intervention by peak plasma concentration (Cmax)

    Characterisation of the effect of heat, occlusion, and moderate exercise on the bioavailability of Test determined by Cmax of R-flurbiprofen and metabolites, if applicable

    Time frame: Day 1 to Day 2 for each period

  3. Assessing the effect of each intervention by area under the plasma concentration versus time curve from patch application to last time point with a concentration value above lower limit of quantitation (AUC0-tlast)

    Characterisation of the effect of heat, occlusion, and moderate exercise on the bioavailability of Test determined by AUC0-tlast of R-flurbiprofen and metabolites, if applicable

    Time frame: Day 1 to Day 4 for each period

  4. Assessing the effect of each intervention by area under plasma concentration versus time curve from patch application to infinity (AUC0-inf)

    Characterisation of the effect of heat, occlusion, and moderate exercise on the bioavailability of Test determined by AUC0-inf of R-flurbiprofen and metabolites, if applicable

    Time frame: Day 1 to Day 4 for each period

  5. Assessing the effect of each intervention by percentage of area under the plasma concentration versus time curve extrapolated to infinity to area under the plasma concentration versus time curve from 0 hour to infinity (AUCexpol%)

    characterisation of the effect of heat, occlusion, and moderate exercise on the bioavailability of Test determined by AUCexpol% of S flurbiprofen as well as R flurbiprofen and their metabolites, if applicable

    Time frame: Day 1 to Day 4 for each period

  6. Assessing the effect of each intervention by concentration at the last time point with concentration value above lower limit of quantitation (Clast)

    characterisation of the effect of heat, occlusion, and moderate exercise on the bioavailability of Test determined by Clast of S flurbiprofen as well as R flurbiprofen and their metabolites, if applicable

    Time frame: Day 1 to Day 2 for each period

  7. Assessing the effect of each intervention by time point to reach peak plasma concentration (Tmax)

    characterisation of the effect of heat, occlusion, and moderate exercise on the bioavailability of Test determined by Tmax of S flurbiprofen as well as R flurbiprofen and their metabolites, if applicable

    Time frame: Day 1 to Day 4 for each period

  8. Asssessing the effect of each intervention by last time point with concentration value above the lower limit of quantitation (Tlast)

    characterisation of the effect of heat, occlusion, and moderate exercise on the bioavailability of Test determined by Tlast of S flurbiprofen as well as R flurbiprofen and their metabolites, if applicable

    Time frame: Day 1 to Day 4 for each period

  9. Assessing the effect of each intervention by apparent terminal elimination half-life (T1/2)

    characterisation of the effect of heat, occlusion, and moderate exercise on the bioavailability of Test determined by T1/2 of S flurbiprofen as well as R flurbiprofen and their metabolites, if applicable

    Time frame: Day 1 to Day 4 for each period

  10. Assessing the effect of each intervention by apparent terminal elimination rate constant determined by log-linear regression (Lz)

    characterisation of the effect of heat, occlusion, and moderate exercise on the bioavailability of Test determined by Lz of S flurbiprofen as well as R flurbiprofen and their metabolites, if applicable

    Time frame: Day 1 to Day 4 for each period

  11. Assessing the effect of each intervention by time point before first concentration balue above the lower limit quantitation (Tlag)

    characterisation of the effect of heat, occlusion, and moderate exercise on the bioavailability of Test determined by Tlag of S flurbiprofen as well as R flurbiprofen and their metabolites, if applicable

    Time frame: Day 1 to Day 2 for each period

  12. Characterization of EFTS adhesion

    measuring patch adhesion area by percentage of visually by site staff with remaining patch adhered

    Time frame: Day 2 for each period

  13. Characterization of local tolerability

    Assessing the local tolerability by using the 8-point dermal response and other effects score according to FDA recommendation

    Time frame: with in 5 minutes after removal of each patch as well as 12 hours, 24 hours, and 36 hours after removal for each period

  14. Recording adverse event and serious adverse event

    Time frame: Day 1 to Day 4 for each period

  15. Residual amount

    residual amout of S-flurbiprofen in used patch for each period

    Time frame: Day 2 for each period

07

Study locations

1 site
  • SocraTec R&D GmbH Clinical Pharmacology Unit
    Mainzerhofplatz, Erfurt 99084, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2025 to primary completion in Apr 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2025
First posted
Mar 11, 2025
StartActual
Feb 28, 2025
Primary completionActual
Apr 3, 2025
CompletionActual
Apr 14, 2025
Last update
Apr 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06870422
Lead sponsor
Teikoku Seiyaku Co., Ltd.
Collaborators
SocraTec R&D GmbH, SocraMetrics GmbH, HWI pharma services GmbH
Responsible party
Sponsor
First posted
Mar 11, 2025
Start date
Feb 28, 2025
Primary completion
Apr 3, 2025
Completion
Apr 14, 2025
Last update
Apr 22, 2025

Study contacts

Kenichi Nishiyama
study chair · Teikoku Seiyaku Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion